Alternative possibilities of hyaluronic acid in genitourinary symptoms treatment

Authors

DOI:

https://doi.org/10.18370/2309-4117.2021.59.92-100

Keywords:

genitourinary menopausal syndrome, atrophic colpitis, reparative processes, promestrienum, hyaluronic acid, Revitaxa gel

Abstract

Research objective: to evaluate the clinical efficacy of vaginal gel with hyaluronic acid Revitaxa gel in comparison with synthetic estrogen-like topical agent in the treatment of women with genitourinary syndrome, to determine the recurrence rate of atrophic changes as a result of these schemes.
Materials and methods. The study included 60 women with genitourinary manifestations and atrophic changes of the vaginal mucosa and cervical epithelium. Clinical, cytological and colposcopic studies were performed to analyze the vaginal epithelium, vaginal microbiocenosis and vaginal tissues. All women with an inflammatory type of smear were prescribed vaginal rehabilitation before the study. Repeated laboratory examination after anti-inflammatory, antibacterial topical therapy confirmed no pathogenic microflora, but signs of atrophy persisted in all women. All women are prescribed local treatment to improve the reparative processes of the vaginal mucosa. The main group (30 women) used Revitaxa gel for local therapy; the control group (30 women) used vaginal suppositories with the synthetic estrogen-like agent promestrienum.
Results. Cytological remission after treatment was observed in all women of the control group and in 76.7% of patients in the main group. Restoration of the vaginal mucosa was detected in all patients of the control group and in 90% of patients in the main group. Repeated examinations 4 months after the end of therapy determined no recurrence of atrophic colpitis in 53.3% of patients in the main group and in 30% of women in the control group. Preservation of a favorable estatrophic type of smears was observed in 43.3% of women of group I and 13.3% of patients of group II (p <0.05), which indicates a more stable effect of hyaluronic acid compared with estrogen-like agent.
Conclusions. Vaginal gel with hyaluronic acid Revitaxa gel in women with genitourinary syndrome gives results similar to the synthetic estrogen-like drug with promestrienum for topical treatment according to colposcopy, cytology, hormonal colpocytology and clinical indicators. Therefore, Revitaxa gel may be recommended for effective use in women with atrophic colpitis who refuse or have contraindications for topical hormonal agents.

Author Biographies

A.A. Sukhanova, Shupyk National Healthcare University of Ukraine, Kyiv

MD, professor, Obstetrics, Gynecology and Reproductology Department

V.V. Sumenko, Shupyk National Healthcare University of Ukraine, Kyiv

PhD, head of the laboratory of Ukrainian State Institute of Reproduction, researcher, Obstetrics, Gynecology and Reproductology Department

R.R. Tkachuk, Kyiv City Center of Reproductive and Perinatal Medicine; Shupyk National Healthcare University of Ukraine, Kyiv

PhD, head of the Obstetrical Department;

Researcher, Obstetrics, Gynecology and Reproductology Department,

References

  1. AMAG Pharmaceuticals. Intrarosa (prasterone) vaginal insert. Prescribing Information (2018).
  2. Archer, D.F., Labrie, F., Bouchard, C., et al. “Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).” Menopause 22.9 (2015): 950–63.
  3. Archer, D.F., Labrie, F., Montesino, M., Martel, C. “Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 μg estradiol on symptoms of vulvovaginal atrophy.” J Steroid Biochem Mol Biol 174 (2017): 1–8. DOI: 10.1016/j.jsbmb.2017.03.014
  4. Baber, R.J., Panay, N., Fenton, A. “IMS recommendations on women’s midlife health and menopause hormone therapy.” Climacteric 19.2 (2016): 109–50. DOI: 10.3109/13697137.2015.1129166
  5. Chen, J., Geng, L., Song, X., et al. “Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial.” J Sex Med 10.6 (2013): 1575–84.
  6. Di Donato, V., Schiavi, M.C., Iacobelli, V., et al. “Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy.” Maturitas 121 (2019): 86–92.
  7. Di Donato, V., Schiavi, M.C., Iacobelli, V., et al. “Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety.” Maturitas 121 (2019): 93–100.
  8. Duchesnay Inc. Osphena (ospemifene) tablets: prescribing information (2019).
  9. Ilhan, G., Aslan, M.M., Cevrioglu, A.S., et al. “Clinical Efficacy of Hormonal and Nonhormonal Agents in the Treatment of Vulvovaginal Atrophy.” J Menopausal Med 27.1 (2021): 15–23. DOI: 10.6118/jmm.20026
  10. Jokar, A., Davari, T., Asadi, N., et al. “Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial.” Int J Community Based Nurs Midwifery 4.1 (2016): 6–78.
  11. Kagan, R., Kellogg-Spadt, S., Parish, S.J. “Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause.” Drugs Aging 36.10 (2019): 897–908. DOI: 10.1007/s40266-019-00700-w
  12. Kingsberg, S.A., Krychman, M.L. “Resistance and barriers to local estrogen therapy in women with atrophic vaginitis.” J Sex Med 10.6 (2013): 1567–74. DOI: 10.1111/jsm.12120.
  13. Kosilova, S.E. “Search for new methods of treatment and prevention of atrophic vaginitis in the postmenopausal period.” Woman’s Health 1.137 (2019): 110–2. DOI: 10.15574/HW.2019.137.110
  14. Labrie, F., Archer, D.F., Koltun, W., et al. “Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.” Menopause 23.3 (2016): 243–56. DOI: 10.1097/gme.0000000000000571
  15. Labrie, F., Archer, D.F., Koltun, W., et al. “Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.” Menopause 23.3 (2016): 243–56. DOI: 10.1097/GME.0000000000000571
  16. Lethaby, A., Ayeleke Reuben Olugbenga, Roberts, H. “Local oestrogen for vaginal atrophy in postmenopausal women.” Cochrane Database Syst Rev 8 (2016): CD001500. DOI: 10.1002/14651858.CD001500.pub3
  17. Maris, E., Salerno, J., Hédon, B., Mares, P. “Management of vulvovaginal atrophy: Physical therapies. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines.” Gynecol Obstet Fertil Senol 49.5 (2021): 414–9. DOI: 10.1016/j.gofs.2021.03.021
  18. Origoni, M., Cimmino, C., Carminati, G., et al. “Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective, observational study.” Eur Rev Med Pharmacol Sci 20.20 (2016): 4190–5.
  19. Pérez-López, F.R., Vieira-Baptista, P., Phillips, N., et al. “Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy.” Gynecol Endocrinol (2021). DOI: 10.1080/09513590.2021.1931100
  20. Photiou, L., Lin, M.J., Dubin, D.P., et al. “Review of non-invasive vulvovaginal rejuvenation.” J Eur Acad Dermatol Venereol 34.4 (2020): 716–26. DOI: 10.1111/jdv.16066
  21. Portman, D.J., Gass, M.L.; Vulvovaginal Atrophy Terminology Consensus Conference Panel. “Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.” Maturitas 79.3 (2014): 349–54. DOI: 10.1016/j.maturitas.2014.07.013
  22. Portman, D.J., Goldstein, S.R., Kagan, R. “Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.” Climacteric 22.1 (2019): 65–72.
  23. Portman, D., Palacios, S., Nappi, R.E., Mueck, A.O. “Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.” Maturitas 78.2 (2014): 91–8. DOI: 10.1016/j.maturitas.2014.02.015
  24. Rioux, J.E., Devlin, M.C., Gelfand, M.M., et al. “17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis.” Menopause 25.11 (2018): 1208–13. DOI: 10.1097/GME.0000000000001220
  25. Romashchenko, O.V., Grygorenko, V.M., Belogolovska, V.V., Babych, O.V. “Prevention and treatment of manifestations of genitourinary menopausal syndrome in women using therapeutic techniques based on platelet-enriched plasma.” Medical aspects of women's health 4–5.125–126 (2019): 21–8.
  26. Simon, J.A., Altomare, C., Cort, S., et al. “Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.” J Womens Health (Larchmt) 27.1 (2018): 14–23.
  27. Simon, J.A., Goldstein, I., Kim, N.N., et al. “The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review.” Menopause 25.7 (2018): 837–47. DOI: 10.1097/gme.0000000000001138
  28. Suckling, J., Lethaby, A., Kennedy, R. “Local oestrogen for vaginal atrophy in postmenopausal women.” Cochrane Database Syst Rev 4 (2006): CD001500. DOI: 10.1002/14651858.CD001500.pub2
  29. The North American Menopause Society (NAMS). “The 2020 genitourinary syndrome of menopause position statement of the NAMS.” Menopause 27.9 (2020): 976–92. DOI: 10.1097/GME.0000000000001609

Downloads

Published

2021-07-22

How to Cite

Sukhanova, A., Sumenko, V., & Tkachuk, R. (2021). Alternative possibilities of hyaluronic acid in genitourinary symptoms treatment. REPRODUCTIVE ENDOCRINOLOGY, (59), 92–100. https://doi.org/10.18370/2309-4117.2021.59.92-100

Issue

No. 59 (2021)

Section

Gynecology

License

Copyright (c) 2021 А.А. Суханова, В.В. Суменко, Р.Р. Ткачук

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.